Consolidation therapy in myeloma: A consolidated approach?

Blood

Volumn 120, Issue 1, 2012, Pages 2-3

  San Miguel, Jesús F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CONSOLIDATION CHEMOTHERAPY; HUMAN; MYELOMA; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84863572165     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-425231     Document Type: Note

References (7)

1. Stewart K, Richardson P, San Miguel J. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-5443.
2. Chanan-Khann AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612-2624.
3. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9-19.
4. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica. 2011;96(9):1246-1248.
5. Nair B, van Rhee F, Shaughnessy JD, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-4173.
6. Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017-4023.
7. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-2084.